Search
Ascendis Pharma A/S
ASNDAdd to Watchlist
230.830USD
-0.320-0.14%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
14.31BMarket Cap
33.26P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Ascendis Pharma A/S is 8.95, ranking 35 out of 389 in the Biotechnology & Medical Research industry. The average price target is 254.00, with a high of 325.00 and a low of 220.00.
Analyst Rating
Based on
20
analysts
Strong Buy
Current Rating
299.582
Target Price
+29.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Ascendis Pharma A/S
ASND
20
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Ascendis Pharma A/S's expected revenue for the next quarter?
Ascendis Pharma A/S's expected revenue is 380.31M.
What is Ascendis Pharma A/S's price target?
Analysts forecast that Ascendis Pharma A/S's price target is USD 254.00, with the highest forecast at USD 325.00 and the lowest forecast at USD 220.00.
How have Ascendis Pharma A/SASND's recent earnings per share performed?
The market expectation was USD 11.79, while Ascendis Pharma A/SASND's earnings per share (EPS) for the previous quarter was USD -0.64. EPS for the next quarter is expected at USD 1.61.
What is the analyst rating for Ascendis Pharma A/S?
Based on the ratings of Ascendis Pharma A/S's stock from 20 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
